Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sorbitol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Sorbitol. Displaying page 1 of 1.
    EudraCT Number: 2022-000491-18 Sponsor Protocol Number: AT-007-1005 Start Date*: 2022-09-14
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Pharmacodynamic Efficacy and Clinical Benefit of AT 007 in Patients with Sorbitol Dehydrogenase (SORD) Deficiency
    Medical condition: SoRbitol Dehydrogenase (SORD) DEficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029328 Neuropathy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005747-42 Sponsor Protocol Number: 1255/08 Start Date*: 2009-02-03
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Efficacy of a medical product containing sorbitol, simethicone and citrate potassium, in comparison with domperidone in patients affected by disfunctional dyspepsia: randomized monocentric cross-ov...
    Medical condition: dysfunctional dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064536 Functional dyspepsia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001728-23 Sponsor Protocol Number: AGO/2017/004 Start Date*: 2017-06-27
    Sponsor Name:Ghent University
    Full Title: Efficacy of golimumab in early axial spondyloarthritis (axSpA) in relation to gut inflammation, an early remission induction study (GO GUT).
    Medical condition: early axial spondyloarthritis (axSpA) in relation to gut inflammation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002378-19 Sponsor Protocol Number: CLN-PXT3003-02 Start Date*: 2015-08-27
    Sponsor Name:PHARNEXT
    Full Title: International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-T...
    Medical condition: Charcot-Marie-Tooth Disease - Type 1A
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Suspended by CA) ES (Completed) BE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003223-53 Sponsor Protocol Number: AGO/2015/008 Start Date*: 2015-12-01
    Sponsor Name:Ghent University Hospital
    Full Title: RANKL-blockade for the treatment of erosive osteoarthritis (OA) of interphalangeal finger joints Randomized, double blind, placebo-controlled study to evaluate the efficacy of denosumab 60mg sc ...
    Medical condition: erosive osteoarthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002325-31 Sponsor Protocol Number: 11.105 Start Date*: 2005-11-04
    Sponsor Name:Taunton & Somerset NHS Trust
    Full Title: Two parallel trials to compare the effectiveness, and potential adverse side-effects, of four routinely used topical therapies to prolong breastfeeding, by either (1) preventing or (2) treating nip...
    Medical condition: Nipple pain in breastfeeding women
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002379-81 Sponsor Protocol Number: CLN-PXT3003-03 Start Date*: 2017-01-26
    Sponsor Name:Pharnext
    Full Title: International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.
    Medical condition: Charcot-Marie-Tooth Disease type 1A
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Suspended by CA) BE (Completed) NL (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023097-40 Sponsor Protocol Number: CLN-PXT3003-01 Start Date*: 2010-11-29
    Sponsor Name:Pharnext
    Full Title: A Phase II, Randomised, Placebo-Controlled Trial of the Safety, Efficacy, Pharmacodynamics of PTX3003 in Patients with Charcot-Marie-Tooth Disease Type 1A
    Medical condition: Charcot-Marie-Tooth disease (type 1A).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023538-22 Sponsor Protocol Number: LY107 Start Date*: 2011-08-30
    Sponsor Name:Lipid Pharmaceuticals
    Full Title: Lýsi sem hægðalyf fyrir börn
    Medical condition: The primary objective of this trial is to investigate the laxative effect of Lysisstílar (Free Fatty Acids suppositories) as compared to Klyx. Participants are children aged 1 year old to 17 year...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004805-30 Sponsor Protocol Number: CLN-PXT3003-06 Start Date*: Information not available in EudraCT
    Sponsor Name:Pharnext SCA
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
    Medical condition: Charcot Marie Tooth Type 1A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005227-42 Sponsor Protocol Number: PM1108357 Start Date*: 2007-08-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, placebo-controlled, parallel study to evaluate the effects of GW-856553 on endothelial function/ vascular compliance in subjects with dyslipidaemia.
    Medical condition: GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000498-56 Sponsor Protocol Number: NL42396.042.12 Start Date*: 2013-09-03
    Sponsor Name:UMCG
    Full Title: 1. Does supported faecal production accelerates the final diagnosis in children with acute abdominal pain? 2. Primary CMV and HHV-6 infection associated with the pathogenesis of acute appendicitis...
    Medical condition: 1. Acute abdominal pain 2. Appendicitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002225-19 Sponsor Protocol Number: FE001 Start Date*: 2016-01-18
    Sponsor Name:Diagnostic Centre of Pécs
    Full Title: Ferumoxytol as an MR contrast agent in CNS and head & neck tumors, intracranial and peripheral vascular disease
    Medical condition: Feraheme will be tested as an MRI contrast agent in the diseases of the central nervous system, in head and neck tumors and peripheral vascular diseases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019388-12 Sponsor Protocol Number: AMAG-FER-CKD-252 Start Date*: 2011-05-12
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subje...
    Medical condition: Nondialysis dependent Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) RO (Ongoing) LT (Prematurely Ended) ES (Temporarily Halted) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019387-37 Sponsor Protocol Number: AMAG-FER-CKD-251 Start Date*: 2011-05-11
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subje...
    Medical condition: Dialysis dependent Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Ongoing) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018961-50 Sponsor Protocol Number: AMAG-FER-IDA-302 Start Date*: 2010-07-02
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Open-label, Active-Controlled Trial Comparing Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency Anemia
    Medical condition: iron deficiency anemia (IDA)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022975 Iron deficiency anemia secondary to blood loss (chronic) LLT
    12.1 10022976 Iron deficiency anemia secondary to inadequate dietary iron intake LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) FR (Completed) LT (Completed) DE (Completed) PL (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004033-42 Sponsor Protocol Number: MKI102428 Start Date*: 2007-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) EE (Completed) FI (Completed) LT (Completed) SI (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001956-20 Sponsor Protocol Number: RLY5016-301 Start Date*: 2013-02-11
    Sponsor Name:Relypsa Inc
    Full Title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
    Medical condition: Hyperkalemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020647 Hyperkalemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SI (Completed) BG (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019550-40 Sponsor Protocol Number: AMAG-FER-CKD-253 Start Date*: Information not available in EudraCT
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) RO (Temporarily Halted) LT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000165-12 Sponsor Protocol Number: RLY5016-205 Start Date*: 2011-05-27
    Sponsor Name:Relypsa, Inc.
    Full Title: A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of RLY5016 in the Treatment of Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy Rece...
    Medical condition: Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10047065 - Vascular disorders 10020772 Hypertension PT
    13.1 10027433 - Metabolism and nutrition disorders 10020647 Hyperkalemia LLT
    13.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) AT (Prematurely Ended) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:55:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA